



## Harrow Health to Present at Aegis Virtual Conference

February 15, 2022

NASHVILLE, Tenn.--(BUSINESS WIRE)--Feb. 15, 2022-- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 23-25, 2022.

To access Harrow Health's presentation, which will begin on Thursday, February 24, 2022, at 3:30 p.m. ET/2:30 p.m. CT, please click on the link to the Aegis conference on the [events section](#) of Harrow Health's website.

### About Harrow Health

Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates [ImprimisRx](#), one of the nation's leading ophthalmology-focused pharmaceutical businesses, and [Visionology](#), a direct-to-consumer eye care subsidiary focused on chronic vision care. Harrow Health also holds non-controlling equity positions in [Eton Pharmaceuticals](#), [Surface Ophthalmics](#) and [Melt Pharmaceuticals](#), all of which started as Harrow Health subsidiaries, and owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, [harrowinc.com](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220214005899/en/): <https://www.businesswire.com/news/home/20220214005899/en/>

Jamie Webb  
Director of Communications and Investor Relations  
[jwebb@harrowinc.com](mailto:jwebb@harrowinc.com)  
615-733-4737

Source: Harrow Health, Inc.